After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss

Core Insights - The global obesity epidemic is driving pharmaceutical companies to invest in weight management solutions, resulting in increased clinical trials for anti-obesity medications [1] Group 1: Eli Lilly's Orforglipron Trial Results - Eli Lilly's Phase 3 trial of orforglipron demonstrated superior weight maintenance over 52 weeks compared to placebo after initial treatment with high doses of Wegovy or Zepbound [2][4] - At one year, orforglipron met primary and key secondary endpoints, showing effective weight maintenance as an adjunct to a healthy diet and physical activity [3] - Participants switching from Wegovy to orforglipron maintained an average weight difference of 0.9 kg, while those switching from Zepbound maintained an average difference of 5.0 kg [5] Group 2: Safety and Tolerability - The safety profile of orforglipron was consistent with previous studies, with common adverse events being mild-to-moderate gastrointestinal issues [6] - Discontinuation rates due to adverse events were 4.8% for orforglipron from Wegovy, 7.6% for placebo from Wegovy, 7.2% for orforglipron from Zepbound, and 6.3% for placebo from Zepbound [7] - No hepatic safety signals were observed in the trial [7] Group 3: Market Reaction - Eli Lilly's stock rose by 2.20% to $1064.73, nearing its 52-week high of $1111.99 [8]